Terug
50
37
28
14
30
4
36
14
50
51
Dagbereik
€ 142,15
€ 146,63
52-Weeksbereik
€ 53,14
€ 146,63
Volume
125
50D / 200D Gem.
€ 129,34
/
€ 94,40
Vorige Slotkoers
€ 142,15
Koershistorie
Financiële Trends
Sectorvergelijking
vs Technology sector mediaan (621 peers)
| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | 0,1 | 12,3 |
| P/B | 0,0 | 2,9 |
| ROE % | 25,1 | 8,9 |
| Net Margin % | 15,9 | 5,6 |
| Rev Growth 5Y % | 18,2 | 9,2 |
| D/E | 0,0 | 0,3 |
Koersdoel Analisten
Geen analistendekking beschikbaar
Winstschattingen
| Periode | WPA Sch. | Omzet Sch. | Analisten |
|---|---|---|---|
| FY2030 |
€ 1.654,14
€ 1.535,23 – € 1.775,68
|
880 B | 1 |
| FY2029 |
€ 1.620,62
€ 1.504,11 – € 1.739,69
|
860 B | 1 |
| FY2028 |
€ 1.347,03
€ 1.250,19 – € 1.446,00
|
780 B | 1 |
Belangrijkste Punten
Revenue grew 18,20% annually over 5 years — strong growth
Earnings grew 40,93% over the past year
ROE of 25,10% indicates high profitability
Net margin of 15,91% shows strong profitability
Debt/Equity of 0,01 — conservative balance sheet
Generating 45,67B in free cash flow
Groei
Revenue Growth (5Y)
18,20%
Revenue (1Y)23,84%
Earnings (1Y)40,93%
FCF Growth (3Y)-7,27%
Kwaliteit
Return on Equity
25,10%
ROIC23,93%
Net Margin15,91%
Op. Margin21,70%
Veiligheid
Debt / Equity
0,01
Current Ratio2,00
Interest Coverage1005,06
Waardering
P/E Ratio
0,14
P/B Ratio0,03
EV/EBITDA-0,90
Dividend Yield0,02%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 23,84% | Revenue Growth (3Y) | 16,48% |
| Earnings Growth (1Y) | 40,93% | Earnings Growth (3Y) | 31,53% |
| Revenue Growth (5Y) | 18,20% | Earnings Growth (5Y) | 60,04% |
| Profitability | |||
| Revenue (TTM) | 625,27B | Net Income (TTM) | 99,47B |
| ROE | 25,10% | ROA | 14,82% |
| Gross Margin | 37,63% | Operating Margin | 21,70% |
| Net Margin | 15,91% | Free Cash Flow (TTM) | 45,67B |
| ROIC | 23,93% | FCF Growth (3Y) | -7,27% |
| Safety | |||
| Debt / Equity | 0,01 | Current Ratio | 2,00 |
| Interest Coverage | 1005,06 | Dividend Yield | 0,02% |
| Valuation | |||
| P/E Ratio | 0,14 | P/B Ratio | 0,03 |
| P/S Ratio | 0,02 | PEG Ratio | 0,27 |
| EV/EBITDA | -0,90 | Dividend Yield | 0,02% |
| Market Cap | 13,44B | Enterprise Value | -122,40B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 625,27B | 504,92B | 460,83B | 411,87B | 320,32B |
| Net Income | 99,47B | 70,58B | 57,49B | 45,48B | 15,16B |
| EPS (Diluted) | 1022,31 | 608,16 | 592,63 | 463,09 | 154,09 |
| Gross Profit | 235,30B | 182,52B | 155,05B | 134,37B | 88,01B |
| Operating Income | 135,68B | 94,16B | 76,45B | 61,27B | 24,49B |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 671,29B | 676,81B | 562,82B | 459,31B | 382,63B |
| Total Liabilities | 250,60B | 304,90B | 262,88B | 211,51B | 174,08B |
| Shareholders' Equity | 420,64B | 371,87B | 299,89B | 247,72B | 208,38B |
| Total Debt | 4,56B | 8,08B | 28,85B | 44,24B | 43,78B |
| Cash & Equivalents | 140,40B | 167,28B | 173,66B | 131,01B | 60,75B |
| Current Assets | 480,05B | 493,66B | 428,27B | 338,37B | 252,89B |
| Current Liabilities | 239,72B | 286,01B | 237,14B | 175,62B | 120,87B |
Strategiescores
This stock passed the criteria for 10 strategies
Score = fit strength (0–100)
Rank = position among all matches
Custom
Capital Light Compounder
#69 of 219
#500 of 825
#378 of 618
#496 of 670
#138 of 157
#630 of 710
#143 of 203
Custom
Full Throttle
#138 of 146
Custom
Lower Risk
#50 of 141
Custom
Balanced Risk
#45 of 152
Recente Activiteit
Ingestapt
Deep Value Investing (Seth Klarman)
Mar 24, 2026
Ingestapt
Capital Light Compounder
Mar 24, 2026
Ingestapt
Price/Sales Ratio Focus (Ken Fisher)
Mar 24, 2026
Ingestapt
Contrarian Investing (David Dreman)
Mar 24, 2026
Ingestapt
Growth Investing (Philip Fisher)
Mar 24, 2026
Ingestapt
Defensive Investing (Benjamin Graham)
Mar 24, 2026
Ingestapt
Value Investing (Warren Buffett)
Mar 24, 2026
Ingestapt
Full Throttle
Mar 24, 2026
Ingestapt
Balanced Risk
Mar 24, 2026
Ingestapt
Lower Risk
Mar 24, 2026